Y Intercept Hong Kong Ltd Sells 11,812 Shares of TransMedics Group, Inc. $TMDX

Y Intercept Hong Kong Ltd reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 32.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,380 shares of the company’s stock after selling 11,812 shares during the period. Y Intercept Hong Kong Ltd’s holdings in TransMedics Group were worth $2,735,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in TransMedics Group by 1.4% during the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after purchasing an additional 11,241 shares during the period. Marshall Wace LLP boosted its position in shares of TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after purchasing an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Zevenbergen Capital Investments LLC raised its position in shares of TransMedics Group by 112.7% during the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after purchasing an additional 136,995 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in TransMedics Group by 5.5% during the second quarter. Bank of New York Mellon Corp now owns 221,276 shares of the company’s stock worth $29,653,000 after buying an additional 11,599 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TMDX shares. Morgan Stanley raised their target price on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded down $2.09 during midday trading on Wednesday, reaching $136.40. 31,878 shares of the company’s stock traded hands, compared to its average volume of 699,128. The company has a market cap of $4.66 billion, a price-to-earnings ratio of 55.07 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The stock has a 50 day moving average of $133.78 and a 200 day moving average of $123.25. TransMedics Group, Inc. has a one year low of $62.07 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s revenue was up 32.2% on a year-over-year basis. During the same period last year, the firm posted $0.12 EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.